Recently, using a murine-based intracranial glioblastoma model, we demonstrated that in-situ injection of anti-CAIX CAR-T cells not only improved the localization and penetration of CAR-T cells but also avoided off-tumor adverse effects observed with systemic delivery of anti-CAIX CAR-T cells [14]. Here, CA9 is linked to neoplasm.